




Searching News Database: XIENCE
HSMN NewsFeed - 27 Oct 2021
HT Supreme(R) Drug Eluting Stent performs equivalent to best-in-class in the PIONEER III publication
HT Supreme(R) Drug Eluting Stent performs equivalent to best-in-class in the PIONEER III publication
HSMN NewsFeed - 23 May 2018
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
HSMN NewsFeed - 23 May 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
HSMN NewsFeed - 28 Aug 2017
ESC Congress 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
ESC Congress 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
HSMN NewsFeed - 25 Jul 2017
Roxwood Medical Announces Agreement with Abbott for Distribution of Products in U.S.
Roxwood Medical Announces Agreement with Abbott for Distribution of Products in U.S.
HSMN NewsFeed - 7 Nov 2016
Abbott's Absorb(TM) Bioresorbable Stent Approved as the First Fully Dissolving Heart Stent in Japan
Abbott's Absorb(TM) Bioresorbable Stent Approved as the First Fully Dissolving Heart Stent in Japan
HSMN NewsFeed - 16 Mar 2016
Abbott's Absorb(TM), the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee
Abbott's Absorb(TM), the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee
HSMN NewsFeed - 12 Oct 2015
Abbott Announces Positive Clinical Results of Absorb(TM), the Naturally Dissolving Heart Stent
Abbott Announces Positive Clinical Results of Absorb(TM), the Naturally Dissolving Heart Stent
HSMN NewsFeed - 19 May 2015
Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease
Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease
HSMN NewsFeed - 10 Jul 2013
Abbott Announces Approval of Next-Generation XIENCE Xpedition(TM) Drug Eluting Stent System in Japan
Abbott Announces Approval of Next-Generation XIENCE Xpedition(TM) Drug Eluting Stent System in Japan
HSMN NewsFeed - 30 May 2013
Orsiro From BIOTRONIK, Industry's First Hybrid Drug-Eluting Stent, Performs as Best in Class
Orsiro From BIOTRONIK, Industry's First Hybrid Drug-Eluting Stent, Performs as Best in Class
HSMN NewsFeed - 25 Sep 2012
Abbott Announces International Launch of the Absorb(TM) Bioresorbable Vascular Scaffold
Abbott Announces International Launch of the Absorb(TM) Bioresorbable Vascular Scaffold
HSMN NewsFeed - 20 Aug 2012
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
HSMN NewsFeed - 30 May 2012
Kona Medical Secures $30M in Financing to Pursue Novel Hypertension Therapy
Kona Medical Secures $30M in Financing to Pursue Novel Hypertension Therapy
HSMN NewsFeed - 9 Apr 2012
Abbott Receives Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in Japan
Abbott Receives Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in Japan
HSMN NewsFeed - 22 Mar 2012
OrbusNeich's Genous(TM) Technology Effectively Promotes Endothelialization and Reduces Thrombogenicity
OrbusNeich's Genous(TM) Technology Effectively Promotes Endothelialization and Reduces Thrombogenicity
HSMN NewsFeed - 4 Nov 2011
Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011
Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011
HSMN NewsFeed - 1 Nov 2011
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
HSMN NewsFeed - 4 Apr 2011
Medtronic Resolute(R) Drug-Eluting Stent Delivers Compelling Clinical Outcomes in Major Studies
Medtronic Resolute(R) Drug-Eluting Stent Delivers Compelling Clinical Outcomes in Major Studies
HSMN NewsFeed - 28 Mar 2011
Medtronic to Unveil Pivotal U.S. Data on Resolute(R) Drug-Eluting Stent at ACC.11
Medtronic to Unveil Pivotal U.S. Data on Resolute(R) Drug-Eluting Stent at ACC.11
HSMN NewsFeed - 30 Sep 2010
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
HSMN NewsFeed - 22 Sep 2010
Medtronic's Resolute Drug-Eluting Stent Shows Strong Performance in Second 'All Comers' Study
Medtronic's Resolute Drug-Eluting Stent Shows Strong Performance in Second 'All Comers' Study
HSMN NewsFeed - 26 May 2010
Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
HSMN NewsFeed - 25 May 2010
Medtronic's Resolute(R) Drug-Eluting Stent Matches Market-Leading Rival in Large Head-to-Head Study
Medtronic's Resolute(R) Drug-Eluting Stent Matches Market-Leading Rival in Large Head-to-Head Study
HSMN NewsFeed - 8 Jan 2010
Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
HSMN NewsFeed - 23 Sep 2009
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
HSMN NewsFeed - 14 Sep 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
HSMN NewsFeed - 31 Aug 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
HSMN NewsFeed - 19 May 2009
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
HSMN NewsFeed - 1 Apr 2009
Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
HSMN NewsFeed - 12 Mar 2009
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
HSMN NewsFeed - 17 Dec 2008
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
HSMN NewsFeed - 10 Oct 2008
Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
HSMN NewsFeed - 15 Sep 2008
Medtronic Starts U.S. and International Trials of Endeavor(R) Resolute Drug-Eluting Coronary Stent
Medtronic Starts U.S. and International Trials of Endeavor(R) Resolute Drug-Eluting Coronary Stent
HSMN NewsFeed - 31 Mar 2008
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
HSMN NewsFeed - 11 Feb 2008
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
HSMN NewsFeed - 29 Nov 2007
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
HSMN NewsFeed - 5 Nov 2007
Abbott Confirms FDA Advisory Panel to Review XIENCE(TM) V Drug Eluting Stent on November 29
Abbott Confirms FDA Advisory Panel to Review XIENCE(TM) V Drug Eluting Stent on November 29
HSMN NewsFeed - 22 Oct 2007
Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
HSMN NewsFeed - 1 Jun 2007
Abbott Submits XIENCE(TM) V Everolimus Eluting Coronary Stent System Application for U.S. FDA Approval
Abbott Submits XIENCE(TM) V Everolimus Eluting Coronary Stent System Application for U.S. FDA Approval
HSMN NewsFeed - 22 May 2007
SPIRIT Clinical Data Reaffirm Strength of TAXUS(R) and PROMUS(TM) Drug-Eluting Coronary Stent Systems
SPIRIT Clinical Data Reaffirm Strength of TAXUS(R) and PROMUS(TM) Drug-Eluting Coronary Stent Systems
HSMN NewsFeed - 16 Apr 2007
COURAGE, SPIRIT Data May Support Role of Advanced Imaging and Diagnosis With IVUS and FFR
COURAGE, SPIRIT Data May Support Role of Advanced Imaging and Diagnosis With IVUS and FFR
HSMN NewsFeed - 11 Jan 2007
Private-Label Version of Abbott's XIENCE(TM)V Drug-Eluting Coronary Stent System Launches in Europe
Private-Label Version of Abbott's XIENCE(TM)V Drug-Eluting Coronary Stent System Launches in Europe
HSMN NewsFeed - 11 Jan 2007
Boston Scientific Announces First Use of PROMUS(TM) Everolimus-Eluting Stent System
Boston Scientific Announces First Use of PROMUS(TM) Everolimus-Eluting Stent System
HSMN NewsFeed - 4 Jan 2007
French Court Rules in Favor of evYsio Medical Devices in Patent Litigation Against Abbott Laboratories
French Court Rules in Favor of evYsio Medical Devices in Patent Litigation Against Abbott Laboratories
HSMN NewsFeed - 25 Oct 2006
Safety and Efficacy Benefits of Next-Generation TAXUS(R) Liberte(TM) Stent Sustained at Twelve Months
Safety and Efficacy Benefits of Next-Generation TAXUS(R) Liberte(TM) Stent Sustained at Twelve Months
HSMN NewsFeed - 3 Oct 2006
Abbott Begins Early International Launch of XIENCE(TM) V Everolimus Eluting Coronary Stent System
Abbott Begins Early International Launch of XIENCE(TM) V Everolimus Eluting Coronary Stent System
HSMN NewsFeed - 5 Sep 2006
Abbott's XIENCE V(TM) Drug-Eluting Coronary Stent Superior to TAXUS(R) Stent in SPIRIT II Clinical Trial
Abbott's XIENCE V(TM) Drug-Eluting Coronary Stent Superior to TAXUS(R) Stent in SPIRIT II Clinical Trial
HSMN NewsFeed - 1 Sep 2006
PROMUS(TM) Everolimus-Eluting Stent Added to Boston Scientific Coronary Stent Portfolio
PROMUS(TM) Everolimus-Eluting Stent Added to Boston Scientific Coronary Stent Portfolio
HSMN NewsFeed - 14 Aug 2006
Abbott Enrolls First Patient in New Clinical Trial of XIENCE(TM) V Drug Eluting Stent
Abbott Enrolls First Patient in New Clinical Trial of XIENCE(TM) V Drug Eluting Stent
HSMN NewsFeed - 24 Jan 2006
Guidant Receives Recommendation for Approval from European Competent Authority for Drug Eluting Stent
Guidant Receives Recommendation for Approval from European Competent Authority for Drug Eluting Stent
Additional items found! 7

Members Archive contains
7 additional stories matching:
XIENCE
(Password required)
XIENCE
(Password required)